CAMKK2 and cancer: In addition, our work proves Drosophila as a powerful model for the rational design of targeted therapies for genetic subsets of RAS-driven cancers, and suggests that the LKB1 subset of KRAS-driven cancers may benefit from targeting of the CAMKK/AMPK circuit.